医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The First Smart Dispensing Robot EVV220 in Asia at Vejthani Hospital

2012年10月17日 PM05:55
このエントリーをはてなブックマークに追加


 

BANGKOK

Vejthani Hospital Bangkok offers cutting-edge technologies, with the ability to operate maximum safety and accuracy. We are thrilled to be the first hospital in Asia to have the new modern advanced technology, The Smart Dispensing Robot EVV220.

Vejthani Hospital Smart Dispensing Robot EVV220 is designed to reduce or eliminate the risk of cross contamination, simplifies a filling process, easy to use, incorporate and keep.

Advantages of Smart Dispensing Robot EVV220

  • The doctor’s order transmits directly to the Smart Robot.
  • Robotic Direct Fill
    - Vials are filled directly from the drug cassette, eliminating the risk of contamination and calibration errors.
  • Complete and Accurate Dispensing Robot
    - Doctor’s order transmits directly to the Smart Robot and verifies the barcode with the barcode scanner to locate corresponding vials.
  • The barcode scanner assures the right medication is refilled into its proper cassette.

Vejthani Hospital Bangkok became the first hospital in Asia to offer Smart Dispensing Robot EVV220, thus can improve the quality services offered in both inpatients and outpatients as well. Indeed modern advanced technology is going to have an even tremendous part in terms of quality healthcare services both local and international countries. If you want more information don’t hesitate to contact us.

Please Visit: Smart Dispensing Robot EVV220

CONTACT

Vejthani
Hospital

Harriet Marie, (+66)85-223-8888
Nurse
Information Online
webmaster@vejthani.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗